Philogen (PHIL) Q1 2025 earnings summary

Executive summary

• Net financial position at March 31, 2025, was positive at €93.6 million, down 8.4% from December 31, 2024.

• Main clinical trials (Nidlegy™ and Fibromun) are progressing on schedule, with positive industrial activity evolution.

• Five new Phase I clinical programs launched in the last three years; at least two more expected in Phase I within 24 months.

• Initiated a share buyback program with a maximum outlay of €5.75 million, up to 250,000 shares.

Financial highlights

• Group liquidity at March 31, 2025, was €104.6 million, down 8.0% from €113.7 million at year-end 2024.

• Net financial debt decreased to €11.0 million from €11.5 million, reflecting lease amortization.

• Cash outflows included €8.3 million for operating costs, €0.5 million capex, and €0.7 million for treasury shares.

• €5 million of liquidity invested in short-term time deposits at market rates.

Outlook and guidance

• Sufficient liquidity to complete registration studies for Nidlegy™ and Fibromun and invest in new experimental drugs.

• At least two additional drugs expected to enter Phase I trials in the next 24 months.

• Awaiting key clinical trial events for Fibromun and Nidlegy™ by mid-2025; Glioblastoma trial completion expected early 2026.